🇺🇸 FDA
Pipeline program

JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet

77242113CRD3001

Phase 3 small_molecule active

Quick answer

JNJ-77242113, Icotrokinra, JNJ-77242113-AAC Placebo tablet for Moderately to Severely Active Crohn's Disease is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Moderately to Severely Active Crohn's Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials